{"title":"Potential therapeutic benefits of lutein-loaded hydrogel in diabetic-induced dermal wound healing.","authors":"Zuha Rahman, Vidhu Aeri","doi":"10.1080/1061186X.2026.2639022","DOIUrl":null,"url":null,"abstract":"<p><p>Research on wound-healing agents is a growing area in modern biomedical sciences, and oxidative stress plays a significant role in the challenges of chronic wound healing. These challenges include dry dressings that lack functionality and cause increased pain by adhering to wounds. Hydrogels are widely utilised for wound healing because they mimic the native extracellular matrix (ECM) and help maintain a moist environment. <i>In silico</i> docking studies revealed that lutein forms strong and stable interactions with proteins involved in ECM degradation, inflammation and oxidative stress. The optimised hydrogel formulations demonstrated excellent physicochemical stability and improved topical delivery of the drug. <i>In vitro</i> and <i>ex vivo</i> studies confirmed superior skin permeation and sustained release of lutein from the fermented hydrogel compared with controls. <i>In vivo</i> experiments using F2 formulation (0.5% lutein) on diabetic rat models demonstrated rapid wound contraction, achieving 92.1% closure by day 9 and complete healing by day 11, with minimal scarring and enhanced tissue regeneration. Histopathological analysis supported these results, revealing dense granulation tissue, minimal inflammatory infiltration and notable dermal remodelling in the treatment group. These findings suggest that lutein-loaded hydrogels are promising biotherapeutic options for the effective management of diabetic wounds.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1568-1577"},"PeriodicalIF":4.7000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Targeting","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1061186X.2026.2639022","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Research on wound-healing agents is a growing area in modern biomedical sciences, and oxidative stress plays a significant role in the challenges of chronic wound healing. These challenges include dry dressings that lack functionality and cause increased pain by adhering to wounds. Hydrogels are widely utilised for wound healing because they mimic the native extracellular matrix (ECM) and help maintain a moist environment. In silico docking studies revealed that lutein forms strong and stable interactions with proteins involved in ECM degradation, inflammation and oxidative stress. The optimised hydrogel formulations demonstrated excellent physicochemical stability and improved topical delivery of the drug. In vitro and ex vivo studies confirmed superior skin permeation and sustained release of lutein from the fermented hydrogel compared with controls. In vivo experiments using F2 formulation (0.5% lutein) on diabetic rat models demonstrated rapid wound contraction, achieving 92.1% closure by day 9 and complete healing by day 11, with minimal scarring and enhanced tissue regeneration. Histopathological analysis supported these results, revealing dense granulation tissue, minimal inflammatory infiltration and notable dermal remodelling in the treatment group. These findings suggest that lutein-loaded hydrogels are promising biotherapeutic options for the effective management of diabetic wounds.
期刊介绍:
Journal of Drug Targeting publishes papers and reviews on all aspects of drug delivery and targeting for molecular and macromolecular drugs including the design and characterization of carrier systems (whether colloidal, protein or polymeric) for both vitro and/or in vivo applications of these drugs.
Papers are not restricted to drugs delivered by way of a carrier, but also include studies on molecular and macromolecular drugs that are designed to target specific cellular or extra-cellular molecules. As such the journal publishes results on the activity, delivery and targeting of therapeutic peptides/proteins and nucleic acids including genes/plasmid DNA, gene silencing nucleic acids (e.g. small interfering (si)RNA, antisense oligonucleotides, ribozymes, DNAzymes), as well as aptamers, mononucleotides and monoclonal antibodies and their conjugates. The diagnostic application of targeting technologies as well as targeted delivery of diagnostic and imaging agents also fall within the scope of the journal. In addition, papers are sought on self-regulating systems, systems responsive to their environment and to external stimuli and those that can produce programmed, pulsed and otherwise complex delivery patterns.